HC Wainwright Weighs in on GH Research FY2030 Earnings

GH Research PLC (NASDAQ:GHRS) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for GH Research in a research report issued on Monday, March 2nd. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $1.54 for the year. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

GHRS has been the topic of a number of other reports. TD Cowen restated a “buy” rating on shares of GH Research in a report on Monday, January 5th. Royal Bank Of Canada lifted their price objective on shares of GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Canaccord Genuity Group boosted their price objective on shares of GH Research from $35.00 to $39.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Guggenheim reiterated a “buy” rating and issued a $29.00 target price on shares of GH Research in a research note on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Thursday, January 22nd. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, GH Research has a consensus rating of “Moderate Buy” and a consensus target price of $38.75.

GH Research Stock Down 4.4%

Shares of GH Research stock opened at $15.30 on Wednesday. The stock has a market cap of $796.06 million, a P/E ratio of -20.68 and a beta of 1.00. GH Research has a 12-month low of $7.98 and a 12-month high of $19.51. The business’s 50 day moving average is $15.28 and its 200-day moving average is $14.19.

Institutional Trading of GH Research

Several large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new position in shares of GH Research in the second quarter worth $79,000. Virtus Investment Advisers LLC acquired a new stake in GH Research during the second quarter worth about $89,000. Stempoint Capital LP bought a new position in GH Research in the 2nd quarter valued at about $1,229,000. HighVista Strategies LLC acquired a new position in shares of GH Research in the 2nd quarter valued at approximately $637,000. Finally, BNP Paribas Financial Markets raised its position in shares of GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after buying an additional 10,600 shares in the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.